Degron Therapeutics
Degron Therapeutics is developing a new class of small molecule molecular glue degrader (MGD) drugs using their proprietary platform GlueXplorer®. They focus on targeting intractable disease targets with structurally differentiated compounds, advanced screening, and validation systems. Their mission is to develop novel MGDs for historically difficult targets, leveraging proprietary data sets and innovative scaffold chemistry.
Industries
Nr. of Employees
medium (51-250)
Products
HuR-targeting molecular glue degrader clinical candidate (IND cleared)
A first-in-class small-molecule degrader that targets the RNA-binding protein HuR; reported IND clearance by the U.S. FDA to support clinical development in solid tumors.
HuR-targeting molecular glue degrader clinical candidate (IND cleared)
A first-in-class small-molecule degrader that targets the RNA-binding protein HuR; reported IND clearance by the U.S. FDA to support clinical development in solid tumors.
Services
Partnerships to co-discover and co-develop molecular glue degrader programs using the company's library, screening systems, and data resources.
Translational research and preclinical programme execution to advance optimized small-molecule degraders toward IND-enabling studies.
Partnerships to co-discover and co-develop molecular glue degrader programs using the company's library, screening systems, and data resources.
Translational research and preclinical programme execution to advance optimized small-molecule degraders toward IND-enabling studies.
Expertise Areas
- Targeted protein degradation
- Molecular glue degrader discovery
- Small-molecule medicinal chemistry
- High-throughput screening and assay development
Key Technologies
- Molecular glue degrader discovery
- Compound-induced proximity assays
- High-throughput screening
- Ternary complex mechanistic analysis
News & Updates
Following the recognition as one of In Vivo's 2025 Rising Leaders by Citeline’s media outlet In Vivo in April 2025, Dr. Lily Zou, Co-founder and CEO of Degron Therapeutics, recently gave an exclusive interview to Citeline to share insights on the company’s development strategy.
Degron Therapeutics announced that it has received clearance on January 29, 2025, from the U.S. Food and Drug Administration (FDA) the company’s Investigational New Drug (IND) application for DEG6498, a first-in-class HuR (Human antigen R) molecular glue degrader investigational drug.
Dr. Lily Zou, CEO & Co-founder of Degron Therapeutics, was honored with the JLABS Deal of the Year Innovation Award for the $1.2B collaboration between Degron Therapeutics and Takeda Pharmaceuticals to discover and develop novel molecular glue degraders for multiple disease targets.
Following the recognition as one of In Vivo's 2025 Rising Leaders by Citeline’s media outlet In Vivo in April 2025, Dr. Lily Zou, Co-founder and CEO of Degron Therapeutics, recently gave an exclusive interview to Citeline to share insights on the company’s development strategy.
Degron Therapeutics announced that it has received clearance on January 29, 2025, from the U.S. Food and Drug Administration (FDA) the company’s Investigational New Drug (IND) application for DEG6498, a first-in-class HuR (Human antigen R) molecular glue degrader investigational drug.
Dr. Lily Zou, CEO & Co-founder of Degron Therapeutics, was honored with the JLABS Deal of the Year Innovation Award for the $1.2B collaboration between Degron Therapeutics and Takeda Pharmaceuticals to discover and develop novel molecular glue degraders for multiple disease targets.